Clinical Trial

A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A

Study acronym: VOYAGER2
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study will test how different doses of study medicine (Inno8) work in the bodies of people with haemophilia A. The purpose of the study is to see if Inno8 is safe to use for people with haemophilia A. The study medicine is a new medicine that cannot yet be prescribed by doctors. The study will last for about 11 weeks.
Protocol Amendment History 3 changes
notable Trial sites expanded: 22 -> 33 locations 2026-04-25
notable Primary completion pushed: 2026-12-21 -> 2027-02-05 2026-04-25
minor Completion pushed: 2026-12-21 -> 2027-02-05 2026-04-25
Trial Details
NCT Number NCT07220564
Lead Sponsor Novo Nordisk A/S
Conditions Haemophilia A
Enrollment 30 participants
Start Date 2025-10-23
Primary Completion 2027-02-05 (estimated)
Study Completion 2027-02-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-10